Atorvastatin as an Antihypertensive Agent

• Status: Completed
• Trial end date: 2023-01-04
• Target enrollment: 0
• Participant gender: All

Summary

This study is aimed to see the antihypertensive effect of statin (Atorvastatin) as certain animal models have shown that statins have the voltage-gated calcium channel blocking effect. It will be a randomized controlled trial that will be done in Ayub Hospital Complex Abbottabad. After ethical approval, 120 patients with newly diagnosed hypertension belonging to either gender and aged 35 and above will be enrolled in the trial. They will randomly be grouped into two groups with each group comprising 60 patients. One group will be administered Amlodipine 5 mg PO once a day, while the other one will be given 5mg Amlodipine plus 10 mg Atorvastatin. The patients will be examined on a follow-up visit 14 days later and blood pressure will be recorded as per protocols.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Himayat Ullah
• Collaborators: Ayub Teaching Hospital; Khyber Medical University Peshawar
• Treatments: Amlodipine; Atorvastatin

Criteria

Inclusion Criteria:

• The inclusion criteria for the study were all newly diagnosed hypertensive patients aged 35 years and above with normal lipid profile

Exclusion Criteria:

• Patients with a history of dyslipidemias, diabetes mellites, chronic kidney disease, and ischemic heart disease